Showing results (321-330 of 382) with videos related to
Sort By:
Pageof 39
Journal of the National Cancer Institute|May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational ResearchToni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.The Prostate|March 21, 2017
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.The Prostate|January 16, 2016
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trialDanyelle A Winchester, Bora Gurel, Cathee Till, et al.Cancer Prevention Research (Philadelphia, Pa.)|June 26, 2020
Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention TrialLauren M Hurwitz, Ibrahim Kulac, Berrak Gumuskaya, et al.Journal for Immunotherapy of Cancer|November 9, 2016
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.Journal for Immunotherapy of Cancer|May 19, 2016
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and VaccinationChristopher M Jackson, Christina M Kochel, Christopher J Nirschl, et al.Pageof 39